



What is it? Relenza is a new anti-flu
‘designer’ drug, which is being
trumpeted by its manufacturers —
the pharmaceutical giant Glaxo
Wellcome — as the first breakthrough
in flu treatment for 30 years.
Also known as… Zanamivir, GG167 or
4-guanidino-2,4-dideoxy-
2,3-dehydro-N-acetylneuraminic
acid. In other words, it’s an
unsaturated analogue of sialic acid
with a guanidino group substituting
for the hydroxyl group at position 4.
How does Relenza work? It blocks the
action of the enzyme neuraminidase
(also called sialidase) on the surface
of types A and B influenza viruses,
preventing them from spreading to
other cells. Influenza viruses bind to
sialic acids on the surface of host cells
through the viral haemagglutinin
glycoprotein. The haemagglutinin
causes the virus envelope to fuse
with the membrane of the endosome,
allowing the virus ribonucleprotein
(RNP) into the cytoplasm. The RNP
complex then moves to the nucleus
for transcription and amplification.
Newly formed virus RNPs leave the
nucleus and then virus particles bud
from the cell at the plasma
membrane. Normally, neuraminidase
‘untethers’ newly assembled virus
particles bound to sialic acid on the
surface of the cell and on the
glycoproteins of other virus particles,
but neuraminidase inhibitors can
block virus spread at this stage. In
cultured cells, virus aggregates can be
seen at the cell surface when Relenza
is present (see Figure).
How was it discovered? Work on
neuraminidase inhibitors began in the
mid-1970s but it was only after work
on the structure of the neuraminidase
— carried out in the early 1980s in
Australia — that the inhibitors began
to be refined by researchers at the
CSIRO and Monash University.
Relenza was found to be the most
effective of several candidates; its
guanidino group was selected to fit
into a pocket in the neuraminidase
that has two glutamate groups at the
bottom. The initial work had been
partly funded by the Australian
company Biota, and in 1989 Glaxo
Wellcome did a deal with Biota to
fund research and bring any product
to market. Biota receives royalties on
sales of the drug.
Where can I get it? Relenza is
marketed in Australia and New
Zealand and has been approved in
the EU, the US and in Switzerland.
The drug has been recently
submitted for approval in Japan. But
flu sufferers in the UK will have to
wait for Relenza, unless they’re
private patients; it has recently been
at the centre of a stand-off between
Glaxo Wellcome and the UK
government, which has refused
permission for it to be prescribed
within the National Health Service
(NHS). Strong sales of Relenza might
help restore the fortunes of Glaxo
Wellcome, which has seen falling
profits since the patent expired on its
money-spinning ulcer drug, Zantac,
two years ago.
So does Relenza really work? The drug
is highly effective in animal models,
decreasing fever and virus-shedding
in mice and ferrets infected with
influenza. In human trials, the drug
(an aerosol spray) cut the severity of
flu symptons by 44% and reduced
recovery time by about one third.
The elderly are at most risk from
flu-related death but the efficacy of
Relenza within this group has yet to
be demonstrated convincingly. There
were only 70 elderly patients among
the 6,000 in the Relenza clinical
trials, which is why the UK
government is not yet prepared to
allow prescription on the NHS. Glaxo
Wellcome will be running more trials
on older patients this winter.
Are there rivals to Relenza? Yes, several.
Gilead and Hoffmann-La Roche
have a compound GS4104, marketed
as Tamiflu, which can be taken by
mouth. It is not active in itself but in
the body is converted to GS4071, a
neuraminidase inhibitor. Tamiflu is
approved in Switzerland and is likely
to be licensed later this year in the
US and Canada.
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(a) Influenza virus particles dissociate from
the cell surface through the action of the viral
neuraminidase (red). (b) In the presence of a
neuraminidase inhibitor, virus remains
associated with cell-surface sialylated
glycoconjugates through its haemagglutinin
(green) and is found in aggregates.
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